Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/10/2021
• Auteurs : Jean-Christophe CorvolJean‐philippe AzulayBjörn BosseYves DauvilliersLuc DefebvreFabian KlostermannNorbert KovacsDavid MaltêteWilliam G OndoRajesh PahwaWerner ReinStéphane ThoboisMartin ValisAleksandar VidenovicOlivier J. Rascol
• Organismes : Institut du Cerveau = Paris Brain Institute NS-Park/FCRIN Network Institut de Neurosciences de la Timone NS-Park/FCRIN Network Hôpital Gui de Chauliac [CHU Montpellier] CHU Montpellier = Montpellier University Hospital Université de Montpellier Département de neurologie [Lille] NS-Park/FCRIN Network Charité - UniversitätsMedizin = Berlin University Medicine University of Pécs Medical School Service de neurologie [Rouen] NS-Park/FCRIN Network Center for neurogenetics [Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York] University of Kansas Medical Center [Kansas City, KS, USA] Theranexus [Lyon] Institut des sciences cognitives Marc Jeannerod - Centre de neuroscience cognitive - UMR5229 Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] NS-Park/FCRIN Network Univerzita Karlova [Praha, Česká republika] = Charles University [Prague, Czech Republic] Massachusetts General Hospital [Boston] Centre Hospitalier Universitaire de Toulouse NS-Park/FCRIN Network
• Publié dans Movement Disorders le 31/10/2020

---

Résumé : Background Excessive daytime sleepiness (EDS) is a frequent and disabling symptom of Parkinson's disease (PD) without approved treatment. THN102 is a novel combination drug of modafinil and low-dose flecainide. Objective The aim of this study is to evaluate the safety and efficacy of THN102 in PD patients with EDS. Methods The method involved a randomized, double-blind, placebo-controlled, crossover trial testing two doses of THN102 (200 mg/d modafinil with 2 mg/d [200/2] or 18 mg/d flecainide [200/18]) versus placebo; 75 patients were exposed to treatment. The primary endpoint was safety. The primary efficacy outcome was the change in Epworth Sleepiness Scale (ESS) score. Results Both doses of THN102 were well tolerated. ESS significantly improved with THN102 200/2 (least square means vs. placebo [95% confidence interval, CI]: −1.4 [−2.49; −0.31], P = 0.012) but did not change significantly with the 200/18 dosage. Conclusions THN102 was well tolerated and showed a signal of efficacy at the 200/2 dose, supporting further development for the treatment of EDS in PD. © 2021 International Parkinson and Movement Disorder Society

---

Fichiers liés : Corvol et al. - THN 102 for Excessive Daytime Sleepiness Associate.pdf

---

Source

---

• Type de publi. :
• Date de publi. : 27/10/2021
• Auteurs : Philippe DouchetJérôme BoissierStephen MuleroHubert FertéMargot DobervaJean-François AllienneEve ToulzaKévin BéthuneOlivier Rey
• Organismes : Interactions Hôtes-Pathogènes-Environnements Interactions Hôtes-Pathogènes-Environnements Interactions Hôtes-Pathogènes-Environnements Epidémiosurveillance de protozooses à transmission alimentaire et vectorielle Université de Reims Champagne-Ardenne Laboratoire de Biodiversité et Biotechnologies Microbiennes Interactions Hôtes-Pathogènes-Environnements Interactions Hôtes-Pathogènes-Environnements Diversité, adaptation, développement des plantes Interactions Hôtes-Pathogènes-Environnements

---

Fichiers liés : Douchet-2021-eags.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 26/10/2021
• Auteurs : Lucie Isoline PisellaSara FernandesGuilhem SoléTanya StojkovicCeline TardJean-Baptiste ChansonFrancoise BouhourEmmanuelle Salort-CampanaGuillemette BeaudonnetLouise DebergeFanny DuvalAude Marie GrapperonMarion MasingueAleksandra Nadaj-PaklezaYann PereonFrederique AudicAnthony BehinDiane FriedmanArmelle MagotJean Baptiste NourySarah SouvannanorathKarim WahbiJean Christophe AntoineKevin BigautJean-Philippe CamdessanchéPascal CintasRabab DebsCaroline Espil-TarisLaurent KremerThierry KuntzerPascal LaforetVincent LaugelMartial MallaretMaud MichaudSylvain NolletJuliette SvahnSavine VicartRocio Nur Villar-QuilesIsabelle DesguerreDavid AdamsSandrine Segovia-KuenyGeraldine MerretElhadi HammoudaAnnamaria MolonShahram Attarian
• Organismes : Assistance Publique - Hôpitaux de Marseille Assistance Publique - Hôpitaux de Marseille Groupe hospitalier Pellegrin CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Centre Hospitalier Régional Universitaire [CHU Lille] Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 Centre Hospitalier Universitaire [Strasbourg] Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] Hôpital de la Timone [CHU - APHM] Aix Marseille Université Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Groupe hospitalier Pellegrin Groupe hospitalier Pellegrin Hôpital de la Timone [CHU - APHM] Aix Marseille Université CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Hôpital de la Timone [CHU - APHM] CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Hôpital Raymond Poincaré [AP-HP] Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre Hospitalier Régional Universitaire de Brest CHU Henri Mondor [Créteil] Hôpital Cochin [AP-HP] Paris-Centre de Recherche Cardiovasculaire Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Centre Hospitalier Universitaire de Toulouse CHU Pitié-Salpêtrière [AP-HP] Centre Hospitalier Universitaire de Bordeaux Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire Vaudois = Lausanne University Hospital [Lausanne] Hôpital Raymond Poincaré [AP-HP] Handicap neuromusculaire : Physiopathologie, Biothérapie et Pharmacologies appliquées Centre Hospitalier Universitaire [Strasbourg] Centre Hospitalier Universitaire [CHU Grenoble] [GIN] Grenoble Institut des Neurosciences Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Régional Universitaire de Besançon Hôpital neurologique et neurochirurgical Pierre Wertheimer [CHU - HCL] CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM CHU Pitié-Salpêtrière [AP-HP] Centre de recherche en Myologie – U974 SU-INSERM Hôpital Necker - Enfants Malades [AP-HP] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Association française contre les myopathies Association française contre les myopathies Association française contre les myopathies Assistance Publique - Hôpitaux de Marseille Hôpital de la Timone [CHU - APHM]
• Publié dans Orphanet Journal of Rare Diseases le 27/10/2020

---

Résumé : Background: Due to their health condition, patients with neuromuscular diseases (NMD) are at greater risk of developing serious complications with COVID-19. The objective of this study was to analyze the prevalence of COVID-19 among NMD patients and the risk factors for its impact and severity during the first wave of the pandemic. Clinical data were collected from NMD-COVID-19 patients, between March 25, 2020 and May 11, 2020 in an anonymous survey carried out by expert physicians from the French Health Care Network Filnemus. Results: Physicians reported 84 patients, including: 34 with myasthenia gravis, 27 with myopathy and 23 with neuropathy. COVID-19 had no effect on NMD for 48 (58%) patients and 48 (58%) patients developed low COVID-19 severity. COVID-19 caused the death of 9 (11%) NMD patients. Diabetic patients were at greater risk of dying. Patients with diabetes, hypertension or severe forms of NMD had a higher risk of developing a moderate or severe form of COVID-19. In our cohort, corticosteroids and other immunosuppressants were not significantly associated with higher COVID-19 severity for acquired NMD. Conclusion: During this period, a small percentage of French NMD patients was affected by COVID-19 compared to the general French population and COVID-19 had a limited short-term effect on them. Diabetes, hypertension and a severe degree of NMD were identified as risk factors of unfavorable outcome following COVID-19. Conversely, in our cohort of patients with acquired NMD, corticosteroids or other immunosuppressants did not appear to be risk factors for more severe COVID-19.

---

Fichiers liés : BPH_OJRD_2021_Pisella.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 25/10/2021
• Auteurs : Alain LécureuilPhilippe GuercheCôme EmmeneckerSophie Jasinski
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal

---

Source

---

• Type de publi. :
• Date de publi. : 25/10/2021
• Auteurs : Alain LécureuilPhilippe GuercheCôme EmmeneckerSophie Jasinski
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal Institut Jean-Pierre Bourgin - Sciences du végétal

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 21/10/2021
• Auteurs : Sven FrancquePierre BedossaVlad RatziuQuentin AnsteeElisabetta BugianesiArun SanyalRohit LoombaStephen HarrisonRozalina BalabanskaLyudmila MatevaNicolas LanthierNaim AlkhouriChristophe MorenoJörn SchattenbergDiana Stefanova-PetrovaLuisa VonghiaRégine RouzierMaeva GuillaumeAlexander HodgeManuel Romero-GómezPhilippe Huot-MarchandMartine BaudinMarie-Paule RichardJean-Louis AbitbolPierre BroquaJean-Louis JunienManal Abdelmalek
• Organismes : Universiteit Antwerpen = University of Antwerp Antwerp University Hospital [Edegem] Chercheur indépendant CHU Pitié-Salpêtrière [AP-HP] Newcastle University [Newcastle] Newcastle Upon Tyne Hospitals NHS Foundation Trust Università degli studi di Torino = University of Turin Virginia Commonwealth University University of California [San Diego] Radcliffe Department of Medicine [Oxford] Franco-czech Laboratory for clinical research on obesity Biomedicine Institute of Sevilla [Seville, Spain]
• Publié dans New England Journal of Medicine le 29/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 19/10/2021
• Auteurs : Julien BattistoloEmmanouil GlampedakisLauro DamontiJulien PoissyBruno GrandbastienLaetitia KalbermatterJean‐luc PaganiPhilippe EggimannPierre‐yves BochudThierry CalandraOscar MarchettiFrederic Lamoth
• Organismes : Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne Bern University Hospital [Berne] Unité de Glycobiologie Structurale et Fonctionnelle - UMR 8576 Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne Université de Lausanne = University of Lausanne
• Publié dans Mycoses le 29/11/2016

---

Résumé : AbstractBackgroundThe epidemiology of candidemia is evolving with raising concern about the emergence of intrinsically resistant non‐albicans Candida species and acquisition of antifungal resistance. In addition to microbiological surveys, epidemiological studies including clinical data are needed to assess the impact of candidemia on morbidity and mortality.ObjectivesTo assess the clinical and microbiological trends of candidemia in a Swiss university hospital.Patients/Methods.This single‐centre retrospective study compared the incidence of candidemia, Candida species distribution, antifungal resistance profiles, clinical characteristics and outcomes between two periods separated by one decade.ResultsA total of 170 candidemic episodes were included (68 from period 1, 2004‐2006, and 102 from period 2, 2014‐2017). Incidence of candidemia (0.85 to 0.97 episode/10,000 patient‐days), species distribution (55%–57% C albicans) and antifungal susceptibilities remained unchanged. During period 2, candidemia was more frequently observed in intensive care units (ICU, 38% vs 19% in period 1, P = .01) and amongst older patients (median age 68 vs 59 years old, P < .01) with more immunosuppressive conditions (24% vs 9%, P = .01). Candidemia in period 2 was more frequently followed by septic shock (23% vs 7% in period 1, P = .01) and ICU admission (42% vs 12%, P < .01) and was associated with higher mortality (34% vs 18%, P = .03). Overall, factors associated with mortality in multivariate analyses included cirrhosis, solid malignancies and ICU stay at the time of candidemia.ConclusionsDespite stable incidence, species distribution and antifungal resistance of candidemia, an epidemiological shift of the disease towards older and more critically ill patients was observed, with higher mortality rates.

---

Fichiers liés : P21.58 myc.13376.pdf

---

Source

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 18/10/2021
• Auteurs : Pauline TrapetJean-Pierre RossiValérie NicolasAgnès KlinguerSylvie MazurierPhilippe LemanceauDavid Wendehenne
• Organismes : Agroécologie [Dijon] Agroécologie [Dijon] Agroécologie [Dijon] Agroécologie [Dijon] Agroécologie [Dijon] Agroécologie [Dijon] Agroécologie [Dijon]

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 18/10/2021
• Auteurs : Pierre Soler-CouteauxJean-Philippe Strebler
• Organismes : Université de Strasbourg Centre d'études internationales et européennes
• Publié dans Revue de droit immobilier. Urbanisme - construction le 30/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 15/10/2021
• Auteurs : Camille ThenotRémy BessonPierre SallotJean-Philippe P MonchouxDamien Connétable
• Organismes : Centre interuniversitaire de recherche et d'ingénierie des matériaux Centre d'élaboration de matériaux et d'études structurales Unité Matériaux et Transformations - UMR 8207 SAFRAN Group Centre d'élaboration de matériaux et d'études structurales Centre interuniversitaire de recherche et d'ingénierie des matériaux
• Publié dans Computational Materials Science le 30/10/2020

---

Résumé : This work reexamines the insertion of O atoms in the L10 γ-TiAl system using first-principles calculations and thermodynamic modeling in the independent point defect approximation. It includes a study of intrinsic point defects, the insertion of many alloying elements (more than twenty were considered), as well as a study of their interaction with oxygen. The formation of complex defects composed of either vacancies, anti-sites or solute elements is then studied. Results at the atomic scale show a high segregation of oxygen in titanium-rich environments: oxygen easily segregates onto Ti anti-sites (Ti Al) and alloying elements are located in the vicinity of Al sub-lattices. DFT point-defect energetics shows that there is a clear correlation between the nature and site preference of an alloying element, and the oxygen segregation energy in the vicinity of this solute. The thermodynamic model shows that at equilibrium, oxygen does not occupy isolated interstitial sites but prefers to be located in the vicinity of Ti anti-sites or alloying elements. The effect of this strong segregation on oxygen diffusivity is discussed hereinafter. Results show a strong slowdown in oxygen diffusivity due to intrinsic defects. For Ti/Al > 0.5 ratios, the traps for O diffusion are mainly constituted by Ti anti-sites, and the addition of solutes does not contribute much to the trapping of diffusing O atoms. For Ti/Al < 0.5 ratios however, the contribution of solutes to trapping phenomena can be very important, and a decrease by 1-2 orders of magnitude of effective O diffusion coefficients can be observed for temperatures around 800-1100 K.

---

Fichiers liés : paper_XO_reviewed.pdf

---

Source